research collaborationTRIMTECH lands $411M Biogen deal for neurodegeneration protein degradersCambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal … more ➔
Venture CapitalModerna creator Flagship Pioneering brings £100M AI lab to LondonU.S. biotech venture creator Flagship Pioneering is investing an initial £100 million (€120 million) to establish an AI-focused company-creation lab in London, marking the first expansion of its company-building … more ➔
competitionA wall around China’s labs, and a window for Europe?Washington is moving to choke off U.S. investment in Chinese biotech. For European companies already building pipelines on Chinese science, the squeeze could be an opening, but a narrow one, says long-time … more ➔
Venture CapitalSofinnova closes €725M fund to back Europe’s late-stage biotechsParis-based life sciences investor Sofinnova Partners has closed its second crossover fund at €725 million ($815 million), targeting around 15 biopharma and medtech companies, primarily in Europe. … more ➔
IPOWindward closes $201M IPO, adds $50M from SanofiSwiss biotech Windward Bio Group has closed its Nasdaq IPO, raising $201.2 million (€183 million) from public investors and another $50 million (€45 million) through a concurrent private placement … more ➔
AppointmentsGubra’s board replaces CEO; Commit staffs its first drug program; TECregen names CMOEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: Gubra fires its CEO, Commit strengthens … more ➔
cancer researchOrakl raises $34M to scale AI platform predicting cancer drug responsesParis-based Orakl Oncology has raised an oversubscribed $34 million (€31 million) Series A, co-led by Swedish investor Norrsken VC and French venture firm Singular, to expand its platform combining … more ➔
fundraisingAddex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2Neurosterix, a spinout of Swiss biotech Addex Therapeutics, has raised $105 million (about €94 million) to advance its lead schizophrenia drug into Phase 2 clinical development. The Boston- and Geneva-based … more ➔
small moleculeLakefront abandons Galapagos-developed TYK2 inhibitor after unsuccessful partnering effortsBelgian biotech Lakefront Biotherapeutics, formerly Galapagos, has discontinued its oral TYK2 inhibitor GLPG3667 after analyzing the drug’s competitive landscape and holding talks with potential partners. … more ➔
fundraisingVectorY secures €74.5M to advance ALS gene therapy trialAmsterdam-based VectorY Therapeutics has secured €74.5 million ($83.5 million) in new financing to advance its lead gene therapy candidate for amyotrophic lateral sclerosis (ALS) and expand its pipeline … more ➔